Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT05330260 Completed - Surgery Clinical Trials

Five Years Follow-up of Neurological Outcome After Minimally Invasive Cardiac Surgery

FUNOMICS
Start date: March 25, 2022
Phase:
Study type: Observational [Patient Registry]

A monocenter observational study will be started to investigate postoperative cognitive dysfunction 5 years after minimally invasive cardiac surgery. Postoperative cognitive dysfunction will be evaluated in three groups: an endoscopic-CABG group (endo-CABG), a PCI (Percutaneous Coronary Intervention) group and a healthy control group. It is hypothesized that the endo-CABG group will show a stronger postoperative cognitive dysfunction compared to the PCI group and the healthy control group.

NCT ID: NCT05329272 Completed - Quality of Life Clinical Trials

Virtual Reality Training Intervention on Cognitive Function and Quality of Life

Start date: January 2017
Phase: N/A
Study type: Interventional

The present study aimed to investigate the effects of a Virtual Reality cognitive training intervention (VRCTI) on cognitive function changes measured with a cognitive test battery and improvement of quality of life in older adults with cognitive impairment in long-term care facilities. Weekly 1-hour sessions were implemented over 8 weeks targeting sustained and selective attention, memory, cognitive functions, and rule deduction. The passive control group received usual care.

NCT ID: NCT05327257 Recruiting - Clinical trials for Mild Cognitive Impairment

iTBS rTMS in Mild Cognitive Impairment

Start date: August 11, 2022
Phase: N/A
Study type: Interventional

The purposes of this research are to test whether it is feasible to administer a treatment protocol called intermittent theta burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS) in adults with mild cognitive impairment (MCI), and to test whether iTBS rTMS treatments can improve memory in mild cognitive impairment (MCI).

NCT ID: NCT05324085 Recruiting - Substance Abuse Clinical Trials

Aerobic Exercise for Cognitive Functioning in Patients With Substance Use Disorder

SO_CogEx
Start date: April 7, 2022
Phase: N/A
Study type: Interventional

Impaired cognitive function is common among patients with substance use disorder (SUD). This is particularly related to executive functions (EF), which includes abilities like decision-making, consequence analysis and impulse/self-control. EF is recognized as an important determinant of treatment outcome as it is associated with dropout rate, attendance to therapy sessions and absence of relapse following treatment termination. Exercise seem to improve cognitive/executive functions, particularly in individuals with cognitive impairments. Aerobic exercise also affects signaling substances and growth factors known to inhibit neural degeneration, and improves cerebral insulin sensitivity and blood flow, contributing to improved brain function. There is a lack of knowledge regarding how to improve EF in SUD patients, and whether such improvements can benefit other parts of the treatment, such as psychotherapy. Aerobic exercise is a well-recognized and cost-effective intervention for cardiovascular and metabolic health, with promising effects on cognitive/executive functions. A randomized controlled trial will be carried out to investigate the effects of aerobic exercise on EF, molecular markers of neuroplasticity and brain function, and treatment outcome in SUD patients. The investigators expect to achieve new knowledge regarding cognitive impairment among SUD patients and to what extent aerobic exercise can improve cognitive abilities and treatment outcome.

NCT ID: NCT05321498 Withdrawn - Alzheimer Disease Clinical Trials

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Start date: June 2023
Phase: Phase 2
Study type: Interventional

The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.

NCT ID: NCT05320523 Recruiting - Parkinson Disease Clinical Trials

Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

Phase 1 study evaluating the safety of combined bilateral globus pallidus internus (GPi) and nucleus basalis of Meynert (NBM) stimulation in treating levodopa responsive motor symptoms of Parkinsonism and cognitive dysfunction, respectively, in patients with moderate to advanced Parkinson's disease having mild cognitive impairment.

NCT ID: NCT05318976 Recruiting - Alzheimer Disease Clinical Trials

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

MINDFuL
Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.

NCT ID: NCT05318937 Completed - Parkinson Disease Clinical Trials

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Start date: July 6, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

NCT ID: NCT05318703 Completed - Clinical trials for Mild Cognitive Impairment

Virtual Exercise For Older Adults With Mild Cognitive Impairment

Start date: January 20, 2021
Phase: N/A
Study type: Interventional

This project is designed to develop and evaluate an Internet-based exercise intervention (tai ji quan Moving to Improve Brain Health) using real-time videoconferencing for older adults with mild cognitive impairment (MCI).

NCT ID: NCT05313529 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

LIGHT-MCI
Start date: October 8, 2022
Phase: N/A
Study type: Interventional

This is a prospective, randomized, open label, parallel, 76-week study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with mild cognitive impairment (MCI).